A Close Examination of Patient Experiences in Bipolar Disorder Clinical Trials
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05891639 |
|
Recruitment Status :
Not yet recruiting
First Posted : June 7, 2023
Last Update Posted : June 7, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what study attributes affect the completion of these specific demographic groups.
This study will investigate the safety and efficacy of bipolar disorder treatments. The focus will be on tracking the rates of completion and withdrawal among these individuals.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future bipolar disorder study.
| Condition or disease |
|---|
| Bipolar Disorder |
| Study Type : | Observational |
| Estimated Enrollment : | 500 participants |
| Observational Model: | Case-Crossover |
| Time Perspective: | Prospective |
| Official Title: | Investigating Factors Affecting Clinical Trial Participation Rates in Patients With Bipolar Disorder |
| Estimated Study Start Date : | June 2024 |
| Estimated Primary Completion Date : | June 2025 |
| Estimated Study Completion Date : | June 2026 |
- Rate of bipolar disorder patients who decide to enroll in a clinical research. [ Time Frame: 3 months ]
- Number of bipolar disorder study participants who remain in clinical research until completion. [ Time Frame: 12 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patient is at least 18 years of age
- Diagnosis of bipolar disorder
- Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria:
- Women of childbearing potential without a negative pregnancy test; or women who are lactating.
- Has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Inability to perform regular electronic reporting
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05891639
| Contact: Michael B Gill | 415-900-4227 | bask@withpower.com |
| United States, California | |
| Power Life Sciences | |
| San Francisco, California, United States, 94107 | |
| Contact: Michael B Gill 415-900-4227 https://www.withpower.com/contact-us@withpower.com | |
| Study Director: | Michael B Gill | Power Life Sciences Inc. |
| Responsible Party: | Power Life Sciences Inc. |
| ClinicalTrials.gov Identifier: | NCT05891639 |
| Other Study ID Numbers: |
81011326 |
| First Posted: | June 7, 2023 Key Record Dates |
| Last Update Posted: | June 7, 2023 |
| Last Verified: | May 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Bipolar Disorder |
|
Bipolar Disorder Bipolar and Related Disorders Mood Disorders Mental Disorders |